Canton Hathaway LLC Boosts Holdings in iShares Biotechnology ETF (NASDAQ:IBB)

Canton Hathaway LLC raised its stake in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 1.0% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 9,961 shares of the financial services provider’s stock after buying an additional 100 shares during the period. Canton Hathaway LLC’s holdings in iShares Biotechnology ETF were worth $1,317,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Sequoia Financial Advisors LLC lifted its holdings in iShares Biotechnology ETF by 8.3% in the third quarter. Sequoia Financial Advisors LLC now owns 2,608 shares of the financial services provider’s stock valued at $380,000 after acquiring an additional 199 shares during the period. NorthCrest Asset Manangement LLC increased its holdings in shares of iShares Biotechnology ETF by 12.3% during the 3rd quarter. NorthCrest Asset Manangement LLC now owns 3,290 shares of the financial services provider’s stock valued at $479,000 after purchasing an additional 360 shares in the last quarter. Riggs Asset Managment Co. Inc. lifted its stake in shares of iShares Biotechnology ETF by 1,314.0% in the 3rd quarter. Riggs Asset Managment Co. Inc. now owns 1,513 shares of the financial services provider’s stock valued at $220,000 after purchasing an additional 1,406 shares during the period. Traynor Capital Management Inc. boosted its holdings in iShares Biotechnology ETF by 11.2% during the third quarter. Traynor Capital Management Inc. now owns 25,004 shares of the financial services provider’s stock worth $3,641,000 after buying an additional 2,525 shares in the last quarter. Finally, Fidelis Capital Partners LLC grew its position in iShares Biotechnology ETF by 8.4% during the third quarter. Fidelis Capital Partners LLC now owns 5,253 shares of the financial services provider’s stock valued at $747,000 after buying an additional 409 shares during the period. Institutional investors and hedge funds own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Down 0.1 %

IBB opened at $138.74 on Tuesday. The company has a fifty day moving average of $135.64 and a two-hundred day moving average of $140.77. iShares Biotechnology ETF has a fifty-two week low of $123.60 and a fifty-two week high of $150.57.

iShares Biotechnology ETF Cuts Dividend

The firm also recently declared a dividend, which was paid on Friday, December 20th. Investors of record on Tuesday, December 17th were issued a $0.0624 dividend. The ex-dividend date of this dividend was Tuesday, December 17th.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.